(News Bulletin 247) – The stock ended the day up nearly 1%. Several analysts made a stock update following the positive Dupixent data.

Barclays today raised its advice on Sanofi from ‘weight online’ to ‘overweight’ following ‘impressive’ clinical results unveiled last week for Dupixent in the treatment of COPD (chronic obstructive pulmonary disease) .

In a study devoted to the European pharmaceutical sector, the analyst now explains that he expects annual sales of 22 billion euros for Dupixent by 2030, against a forecast of 16.5 billion euros until then.

According to him, this development highlights the ‘value’ side of the Sanofi share, that is to say its weakly valued aspect compared to other titles such as GSK or Novartis.

“With investors increasingly concerned about the impact of the Inflation Reduction Act (IRA) on the sector, we consider Sanofi to be protected in the short term,” adds the intermediary. .

The legislation put in place in the United States within the framework of the IRA legislation provides for a cap on drug prices.

Morgan Stanley indicates that it has also raised its target price on the title, which goes from 90 to 115 euros.

Jefferies also reaffirms its ‘buy’ recommendation and its target price of 120 euros on Sanofi, welcoming the publication of positive phase III data for its flagship drug Dupixent in COPD (chronic obstructive pulmonary disease).

“Dupixent significantly reduced exacerbations and improved lung function, and could thus be the first biologic drug approved for this important market opportunity if the second trial is successful in the first half of 2024,” he said.

The broker specifies that its sales estimate for Dupixent of 20 billion euros by 2031 only includes 0.7 billion for COPD, thus implying the potential for upside for the long-term EPS of the health group in the event of success. .

Copyright (c) 2023 News Bulletin 247. All rights reserved.